Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04038710 · ClinicalTrials.gov registry record
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
A clinical trial of Cystic Fibrosis, sponsored by National Jewish Health.
- Completed
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT04038710 is a study of Cystic Fibrosis that has completed, run by National Jewish Health. The registered enrollment target is 8 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04038710, a study of Cystic Fibrosis, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational study of people with severe cystic fibrosis that are eligible for Vertex's triple combination therapy through its expanded access. Pulmonary health, intestinal health, and the overall health of individuals will be tracked for a year to see how effective triple combination therapy is in these people with severe cystic fibrosis disease.
Conditions Studied
Interventions
- DRUG Triple combination therapy
Study Locations (1)
Colorado
- National Jewish Health - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2021-02-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04038710
The ClinicalTrials.gov registry entry for NCT04038710 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (96% lower). The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Triple combination therapy is the first listed.
NCT04038710 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT04038710 about?
NCT04038710 is a clinical study titled "Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.". This is an observational study of people with severe cystic fibrosis that are eligible for Vertex's triple combination therapy through its expanded access. Pulmonary health, intestinal health, and the overall health of individuals will be tracked for a year to see how effective triple combination th...
What is the current status of trial NCT04038710?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2019-09-05. Estimated completion is 2021-02-26.
What conditions does trial NCT04038710 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT04038710?
The interventions under investigation include: Triple combination therapy (DRUG).
Who is sponsoring clinical trial NCT04038710?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04038710 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.